Company Profile
Bicycle Therapeutics Stock Price, News & Catalysts
- Ticker:
- BCYC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom with U
Stock performance
3.79 USD (-5.49%)
Close
Last updated: October 6, 2026
300M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, BCYC closed down 5.49% at $3.79. No new same-company headline was identified in the current news window.
Company overview
Bicyclic Peptide Therapeutics Platform
Bicycle Therapeutics develops medicines built from proprietary bicyclic peptides that bind defined disease targets with antibody-like affinity while retaining small-molecule-like size. The platform supports drug conjugates, radioconjugates, imaging agents, and other precision-targeted modalities.
Nuzefatide Pevedotin
Nuzefatide pevedotin is an EphA2-targeting Bicycle Drug Conjugate carrying a cytotoxic payload. The program is being evaluated in recurrent pancreatic ductal adenocarcinoma and has also generated clinical and preclinical evidence across urothelial, head and neck, and other EphA2-expressing cancers.
Zelenectide Pevedotin
Zelenectide pevedotin targets Nectin-4 and is being studied alone and with pembrolizumab in metastatic urothelial cancer. Its design seeks to preserve antitumor activity while reducing toxicities associated with larger antibody-drug conjugates against the same target.
Bicycle Radioconjugates
The company is expanding into radiopharmaceuticals through Bicycle Radioconjugates, which use rapid tumor targeting and clearance characteristics to deliver radioisotopes. Human imaging studies are used to validate target engagement and support selection of therapeutic candidates.
Partnered Platform Economics
Bicycle also collaborates with pharmaceutical companies that apply its technology to targets outside the company's internally prioritized programs. These partnerships can provide research funding, milestones, and royalties while broadening validation of the underlying platform.
Future catalysts
- Clinical update from the Phase 2 study of nuzefatide pevedotin in recurrent pancreatic cancer as enrollment and follow-up mature.
- Initiation of the first company-sponsored Phase 1 trial of BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in 2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bicycle Therapeutics (BCYC)?
Bicycle Therapeutics (BCYC) most recently closed at 3.79 USD, a -5.49% move versus the previous session.
What is the market cap of Bicycle Therapeutics (BCYC)?
Bicycle Therapeutics currently has a market capitalization of 300M USD on BioPharmSignal.
What does Bicycle Therapeutics do?
Bicyclic Peptide Therapeutics Platform Bicycle Therapeutics develops medicines built from proprietary bicyclic peptides that bind defined disease targets with antibody-like affinity while retaining small-molecule-like size. The platform supports drug conjugates, radioconjugates, imaging agents, and other precision-targeted modalities. Nuzefatide...
On which exchange is BCYC stock listed?
Bicycle Therapeutics (BCYC) is associated with NASDAQ, United Kingdom with U, Biopharma.
What is pembrolizumab?
Zelenectide Pevedotin Zelenectide pevedotin targets Nectin-4 and is being studied alone and with pembrolizumab in metastatic urothelial cancer.
Which conditions is Bicycle Therapeutics targeting with pembrolizumab?
Bicycle Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Bicycle Therapeutics describe recent progress with pembrolizumab?
Clinical update from the Phase 2 study of nuzefatide pevedotin in recurrent pancreatic cancer as enrollment and follow-up mature. Initiation of the first company-sponsored Phase 1 trial of BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in 2027.
What is Bicyclic?
Bicyclic Peptide Therapeutics Platform Bicycle Therapeutics develops medicines built from proprietary bicyclic peptides that bind defined disease targets with antibody-like affinity while retaining small-molecule-like size.